Skip to main content

Table 2 Effect of rosiglitazone treatment on expression levels (ΔCt) of PPARγ, PPARγ responsive genes and NFκB related genes in type 2 diabetic patients1,2

From: Anti-inflammatory effect of rosiglitazone is not reflected in expression of NFκB-related genes in peripheral blood mononuclear cells of patients with type 2 diabetes mellitus

Gene ΔΔCt (after – before treatment) p-value3
PPARγ 0.31 (-0.70 – 1.29) 0.213
CD36 0.37 (-0.93 – 0.90) 0.248
LPL -0.39 (-0.90 – 1.26) 0.248
INFγ -0.53 (-3.04 – 0.62) 0.045
IL1R1 0.37 (-1.16 – 1.51) 0.041
RELB 0.31 (-0.23 – 2.27) 0.016
SLC20A1 0.41 (-1.03 – 1.93) 0.033
  1. 1 The expression of 84 genes related to NFκB was profiles using the RT2Profiler™ PCR Array; n = 11
  2. 2 Values are reported as ΔΔCt values and presented as medians with ranges. A negative ΔΔCt value corresponds with an upregulation and a positive ΔΔCt value with a downregulation of the gene after rosiglitazone treatment.
  3. 3 Gene expression levels (ΔCt values) were analysed with the non-parametric Wilcoxon signed rank test. Differences were considered significant at a p-value < 0.05